C

Cardiff Oncology
D

CRDF

2.45000
USD
-0.06
(-2.20%)
Market Closed
Volume
10,384
EPS
-1
Div Yield
-
P/E
-3
Market Cap
125,277,680
OverviewSignalsIdeasNews
Related Instruments
    B
    BLNK
    -0.08500
    (-5.28%)
    1.52500 USD
    F
    FSR
    0
    (0%)
    0.000000 USD
    H
    HYLN
    -0.11000
    (-4.17%)
    2.53000 USD
    L
    LI
    0.465
    (2.09%)
    22.715 USD
    N
    NIO
    0.06500
    (1.47%)
    4.49500 USD
    P
    PLUG
    -0.10500
    (-5.33%)
    1.86500 USD
    R
    RIDE
    -0.02030
    (-2.74%)
    0.72000 USD
    TSLA
    TSLA
    9.69
    (3.11%)
    352.65 USD
    W
    WKHS
    0.05000
    (4.27%)
    1.22000 USD
    X
    XPEV
    0.100
    (0.79%)
    12.730 USD
    More
News

Title: Cardiff Oncology

Sector: Healthcare
Industry: Biotechnology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").